Press Release

Media Contact
Matthias Link
T +49 6172 609-2872
matthias.link@fresenius.com

Contact for analysts andinvestors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com

December 5, 2018

Fresenius Medical Care announces acquisition of renal hospitals
and dialysis centers in China
Fresenius Medical Care, the world’s largest provider of dialysis products and services,
continues to expand its dialysis care network through the acquisition of further dialysis
centers and renal hospitals in China. The company acquired a 70% share of Guangzhou
KangNiDaiSi Medical Investment Co., Ltd, which focuses on dialysis and related chronic
disease services. KangNiDaiSi has three independent hemodialysis centers underconstruction in the cities of Guangzhou and Zhaoqing in Guangdong province, whichborders Hong Kong in southeast China. A proposed fourth center in Guangzhou awaits
government approval.
Fresenius Medical Care also acquired 55% stakes in Henan Aishen Hospital Management
Co. Ltd (Henan Aishen) and Aishen Beijing Hospital Management Co., Ltd (AishenBeijing). Henan Aishen and Aishen Beijing are building 13 dialysis centers and a grade I
renal hospital to complement the dialysis care network that will cover Henan, Shandong,
Guangdong and Hainan provinces. There are further plans to expand into new locationsin the future. In addition, the company has taken a 60% share of Daqing Kangda Dialysis
Center Co., Ltd in Heilongjiang province.
The acquisitions follow the purchase of Yunnan Kunming Wuhua Healthcare Hospital inApril 2017, and the acquisition of a 70% share of Sichuan Hejiang Kangcheng Renal
Hospital in June 2018 as well as the acquisition of a 70% share of Sichuan ZiyangZhongxin Hospital, both located in the Sichuan province.

Page 1/3

Rice Powell, CEO of Fresenius Medical Care, said: “Fresenius Medical Care is committed
to improving access to world-leading dialysis technology and chronic disease
management services for the more than 120 million people in China who are living withchronic kidney disease. These acquisitions mark an important strategic step in ourbusiness development in China. As the second largest product market, China is alreadytoday an important business growth driver for Fresenius Medical Care. We have been
continuously investing in enhancing our product range within the local market. We havealso started to enter the provider business to introduce advanced dialysis services andoperations management in China.”“As a leading provider of dialysis products and services in China, we are eager to workwith other companies that are dedicated to elevating the treatment of kidney disease inthis huge country. In particular, we focus on increasing access to treatment in rural
areas, where there have traditionally been fewer options for patients,” said Harry de Wit,
CEO of Fresenius Medical Care Asia-Pacific. “We strive to introduce our world-leading
chronic disease management system and high-quality dialysis treatment services
throughout the country. And we will continue to search for opportunities to partner withinstitutions from the public and private sectors and invest in new dialysis centers andrenal hospitals.”
The prevalence of chronic kidney disease (CKD) in China is 10.8% of the adult
population, which equates to more than 120 million people. According to research
conducted by the Chinese Society of Nephrology, there currently are one million ESRD
patients registered in China, but only around 500,000 receive dialysis treatment.

Fresenius Medical Care is the world's largest provider of products and services for individuals withrenal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment.
Through its network of 3,872 dialysis clinics, Fresenius Medical Care provides dialysis treatmentsfor 329,085 patients around the globe. Fresenius Medical Care is also the leading provider of
dialysis products such as dialysis machines or dialyzers. Along with its core business, the company
provides related medical services in the field of Care Coordination. Fresenius Medical Care is listedon the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company’s website at www.freseniusmedicalcare.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual
results could differ materially from those described in these forward-looking statements due to certain factors,
including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate
fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These andother risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S.
Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this release.

Page 2/3

Notes to editors
About Guangzhou KangNiDaiSi Medical Investment Co., Ltd
The business scope of Guangzhou KangNiDaiSi Medical Investment Co., Ltd includes
renal hospital management as well as investment consulting services. The currentcompany focus is on providing hemodialysis and related chronic disease services. Apartfrom owning three independent dialysis centers in Guangzhou and Zhaoqing, which are
currently under construction, there is a forth dialysis center currently under government
approval for Guangzhou, Guangdong.
About Hejiang Kangcheng Renal Hospital
Sichuan Hejiang Kangcheng Renal Hospital will be the key platform and starting point for
Fresenius Medical Care to extend its high-quality dialysis service and chronic disease
control program. The renal hospital treats patients with chronic disease such as diabetesand high blood pressure. As a designated hospital for basic medical insurance in Sichuan
and work-related injury medical insurance in Luzhou, the hospital also provides medicalservices to social security insurance policy holders in the Luzhou area.
Fresenius Medical Care plans to add six more dialysis stations to the hospital in 2019 toserve 120 patients. The company also plans to build a “Kangcheng Chronic Disease
Control Center” to continuously enhance the quality of its dialysis service and expand toneighboring areas in Hejiang county medical network, in addition to fulfilling the medical
needs of patients in the main urban area.
About Henan Aishen Hospital Management Co., LtdHenan Aishen Hospital Management Co., Ltd was founded in April 2012. Its main focus is
the sales of dialysis products and management of dialysis centers. It has establisheddialysis service collaborations with numerous public hospitals in Henan province. Current
projects include the design, construction, staff recruitment and training for independent
dialysis treatment centers. The joint venture is expected to have at least sevenindependent dialysis centers in Henan province during the next months.
About Aishen Beijing Hospital Management Co., Ltd
Aishen Beijing Hospital Management Co., Ltd was founded in September 2010. Thecompany's goal is to expand dialysis treatment service across the country. After years ofcollaborating with other companies, Aishen Beijing Hospital Management Co., Ltd has
accumulated abundant medical resources and built a robust business development
strategy. Its joint venture projects will include the design, construction, staff recruitment
and training for independent dialysis treatment centers. The joint venture is expected tohave at least seven independent dialysis centers in Shandong, Guangdong and Hainan
province during the next months.
About Daqing Kangda Dialysis Center
Daqing Kangda Dialysis Center is an independent dialysis treatment center approved byHealth and Family Planning Commission of Heilongjiang Province. It is located in Datong
District of Daqing with 1,200 square meters and 20 dialysis machines. Renovation of thecenter was completed in April 2018. The center will gradually increase its number ofdialysis stations and will improve the level of its dialysis services by applying Fresenius
Medical Care standards to staff training and medical management.

Page 3/3